Experimental cancer drug trial halted early
NCT ID NCT05252390
First seen Nov 06, 2025 · Last updated Apr 29, 2026 · Updated 23 times
Summary
This early-stage study tested a new drug called NUV-868, alone or combined with other cancer drugs (olaparib or enzalutamide), in 82 adults with advanced solid tumors like ovarian, pancreatic, prostate, or breast cancer. The main goal was to check safety and find the right dose. The study was terminated early, so results may be limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cabrini Hospital Malvern
Malvern, Victoria, 3144, Australia
-
Calvary Mater Hospital Newcastle
Waratah, New South Wales, 2298, Australia
-
Carolina BioOncology Institute
Huntersville, North Carolina, 28078, United States
-
Ellison Institute of Technology
Los Angeles, California, 90064, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
H. Lee Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Laura & Isaac Perlmutter Cancer Center - NYU Langone Health
New York, New York, 10016, United States
-
Linear Clinical Research
Nedlands, Western Australia, 6009, Australia
-
Macquarie University Hospital
North Ryde, New South Wales, 2109, Australia
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
NEXT Virginia
Fairfax, Virginia, 22031, United States
-
Peter Maccallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Rocky Mountain Cancer Centers, LLP
Aurora, Colorado, 80012, United States
-
Rocky Mountain Cancer Centers, LLP
Lone Tree, Colorado, 80124, United States
-
Sarah Cannon Research Institute - Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231, United States
-
Texas Oncology - Fort Worth Cancer Center
Fort Worth, Texas, 76104, United States
-
The University of Arizona Cancer Center
Tucson, Arizona, 85724, United States
-
Virginia Oncology Associates
Norfolk, Virginia, 23502, United States
Conditions
Explore the condition pages connected to this study.